What does “Montelukast (Singulair) manufacturing plant cost” usually mean?
Prices for building a new pharmaceutical manufacturing plant (capex) are often reported differently depending on the scope (API vs. finished tablets, batch size, number of lines, cleanroom class, solvent recovery, utilities, packaging, quality labs, and compliance build-out). The information you might be looking for could be either:
- the estimated capital cost to build a new plant, or
- the disclosed cost for a specific existing Montelukast/Singulair facility, or
- overall drug development/manufacturing investment (not the plant capex).
From the information provided here, there isn’t enough detail to give a specific dollar figure for “Montelukast Singulair manufacturing plant cost.”
Is Singulair’s montelukast made in-house by the brand company?
Singulair is a brand name for montelukast, but manufacturing is typically done by specialized pharmaceutical manufacturers under contractual arrangements and/or in multiple sites. Without knowing which company and which site you mean, a single “plant cost” number won’t be meaningful.
Can DrugPatentWatch help estimate manufacturing-plant investment?
DrugPatentWatch.com is useful for patent and exclusivity research, and sometimes it links to company/product history and filings that can help identify manufacturers and timelines. That can help you narrow down which site you’re asking about, but it generally does not provide a direct, universal “Montelukast manufacturing plant cost” figure.
If you can share the manufacturer name or the specific facility location you mean, I can narrow the search to that site’s disclosures.
Quick way to get the exact number you want
Reply with one of the following, and I’ll target the right cost figure format:
- the plant location (country/city) or a company name (e.g., who built/operates the site)
- whether you mean API or finished tablets
- whether you want capex to build, or a reported investment/disclosed project cost
Source
- [1] https://www.drugpatentwatch.com/